ARTICLES BY JEFFREY S. HANDEN, PH.D.

  • The Human Component Of Clinical Trial Technology Implementations
    The Human Component Of Clinical Trial Technology Implementations

    As part of our ongoing series about best-in-class approaches for rapidly assessing, prototyping, and introducing digital and other clinical trial technologies, we focus our attention in this article on the “human” component of technology-enabled transformation.

  • Leveraging AI To Assess Clinical Trial Technologies
    Leveraging AI To Assess Clinical Trial Technologies

    As part of our ongoing series detailing an approach for the rapid assessment and prototyping of digital and other clinical trial technologies, we introduce here the use of artificial intelligence (AI) and machine learning (ML) to optimize clinical study design and execution. 

  • Building And Applying A Configurable Clinical Study Model
    Building And Applying A Configurable Clinical Study Model

    Last month we introduced an approach for the rapid assessment and prototyping of digital and other clinical trial technologies. Advances in technologies and digital innovations targeting the clinical research environment are evolving at dizzying rates, and the need to efficiently assess and implement opportunities is greater than ever.

  • Assessing And Implementing Clinical Trial Technologies: A 3-Step, Adaptive Approach
    Assessing And Implementing Clinical Trial Technologies: A 3-Step, Adaptive Approach

    It is generally accepted that a significant and unacceptable percentage of IT projects fail. According to one 2017 report, 14 percent of all IT projects were total failures; a remaining 31 percent didn’t meet their goals, while 43 percent were over budget and 49 percent exceeded timelines. .

  • 3 Major Challenges With Global Clinical Trials — And How To Overcome Them
    3 Major Challenges With Global Clinical Trials — And How To Overcome Them

    The disconnect between increased investment/activity and output points to continuing significant challenges in the global clinical trials market. Here we examine three of the leading issues facing the biopharmaceutical industry today.

  • What Does Patient-Centricity Really Mean … And Why Do We Need It?
    What Does Patient-Centricity Really Mean … And Why Do We Need It?

    The challenge to recruit and retain numbers of patients for Phase 3 industry-sponsored trials is not new to the industry. In fact, 48 percent of sites miss their enrollment targets and 80 percent of trials are delayed due to recruitment, but there are new opportunities to achieve recruitment goals while also minimizing dropout. 

Jeffrey S. Handen, Ph.D.

Jeffrey S. Handen, Ph.D.

Jeffrey S. Handen, Ph.D., is a director in the Life Sciences practice at Grant Thornton LLP and a leader in R&D transformation. He has published in multiple peer-reviewed and business journals, presented at numerous industry conferences and scientific meetings as an invited speaker, and served as past editor in chief of the Industrialization of Drug Discovery and Re-inventing Clinical Development compendiums. Handen has more than 20 years’ experience in pharmaceutical and biotechnology R&D, process re-engineering, and systems and process implementation. He is responsible for overseeing business process improvement and solution architecting for optimizing both clinical development and discovery. You can contact him at jeff.handen@us.gt.com.